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To the Editor:
It was interesting to read the paper by RAGHU et al. [1] in the July issue of the European Respiratory Journal
(ERJ). The article evaluated the epidemiology of idiopathic pulmonary fibrosis (IPF) in 18–64 year-olds in
the USA.
The purpose of the article was to update the epidemiological data for IPF among younger US adults and to
complement a recent study that reported the incidence and prevalence of IPF among older Americans in the
Medicare programme [2]. This retrospective study utilised administrative patient claims data from Optum’s
Clinformatics Data Mart MultiPlan Database (Optum, Eden Prairie, MN, USA), related to the time period
2004–2010. The annual cumulative prevalence increased steadily in the first few years (from 13.4 cases per
100000 person-years in 2005 to 18.2 cases in 2010 per 100000 person-years), while the annual incidence of
IPF decreased over time (from 7.9 cases per 100000 person-years in 2005 to 5.8 cases in 2010 per
100000 person-years). The overall incidence decrease was mainly driven by a decreasing trend in the
younger patients (aged 18–44 years), while the incidence in older patients remained stable. The information
provided in the article is very interesting. In our opinion it presents some peculiar and critical issues.
First, it analyses an age range in which IPF is less frequent and suggests that the decreased incidence
observed in younger subjects may be due to advances in our diagnostic ability to distinguish IPF from
similar disorders occurring more frequently in younger age groups. However, the main issues relate to the
use of data from healthcare administrative databases that may potentially be affected by selection biases and
not represent the general population. Table 1 of the article shows the distribution, by census region, of the
population registered in the Optum database in 2010 [1]. Comparing this distribution with that of the actual
American population aged 18–64 years in 2011 (US Census Bureau data), broad differences can be observed:
enrolees in the “Pacific” and “East South Central” regions account for 5.2% and 2.7%, respectively, of the
database analysed by RAGHU at al. [1] while the US population aged 18–64 years residing in these two
regions is 16.4% and 5.9%; and enrolees in the New England region are 17.9% while the residents are 4.7%.
Moreover, since IPF is an age- and sex-specific disease, it is essential that the actual distribution by age and
sex in each area is adequately represented by the sample studied. This is why we believe that the estimates
provided in the paper cannot be extended to the whole American population aged 18–64 years as stated in
the discussion: “Our study reveals the following: 1) we updated the estimates of the epidemiology of IPF
among young adults in the USA from recent national data”, and that the effect of geographical regions as an
independent predictor of the incidence of IPF should be investigated more accurately.
Secondly, when databases collect health data only from workers, as in this study, there is yet another
problem as estimates may be biased by the healthy worker effect. Mortality and morbidity estimates for
workers are lower than those of the general population because people with poor health are usually
excluded from the job market.
Finally, a further issue is the choice of a 1-year washout period to identify IPF cases. The authors say that
this choice affected both the prevalence trend (initial increase followed by a plateau) and the failure to
identify incident cases before 2005. The authors should also consider that with a 1-year washout period
the decrease in IPF incidence may not be an actual decrease since some of the incident cases identified in
the first years of the study could be cases presenting before 2004.
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A Canadian study published in the same issue of the ERJ relied on a 4-year washout period and used
national administrative data to estimate IPF incidence and prevalence in Canada during 2011 [3], hence
data from the entire population. For all ages, the narrow case prevalence was 20.0 per 100000 person-years
and incidence was 9.0 per 100000, with both rates higher in men than in women. The study reported
geographical differences in IPF prevalence (narrow case definition) in the population over 50 years of age,
with lower rates in the western provinces of British Columbia, Alberta, Saskatchewan and Manitoba and
the highest rate in Quebec. This comparison requires a standardisation of the rates if the populations have
a different sex and age distribution.
Although the article analysed a national population and gave an overview of the epidemiology of IPF in
recent years, changes in the incidence and prevalence of IPF could not be assessed given the short period
considered.
In our study conducted using the healthcare administrative databases of Lombardy (a region with nearly
10 million inhabitants and the most populous region in Italy), we analysed the incidence and prevalence of
IPF from 2000 to 2010 and estimated the prevalence and incidence rates for 2005–2010 only, thus allowing a
5-year washout period in order not to confuse incident and prevalent cases [4]. 5 years is an appropriate
period of time for a disease with a median survival of 3–5 years [5]. We believe this is a strong point of our
work and must be taken into account when analysing epidemiology studies. 100% of the population was
analysed because regional administrative data was used and not data from subgroups that may not be
representative of the general population. As in the study by RAGHU et al. [1], we examined the prevalence and
incidence trends in 2005–2010 and similarly observed an increase in the prevalence while the incidence
remained stable at all ages. Although the case identification method used in both studies is identical, a correct
comparison of estimates from different populations (from different geographical areas or over different
periods of time) requires specific statistical approaches. For example, a comparison of the estimates presented
in the 2016 paper by RAGHU et al. [1] and those for the US population in 2000 [6] should rely on standardised
rates, since in the latter study the population analysed was a sample of about 3 million people living in 20 US
states: 28% in the South Atlantic region, 37% in the South Central region and 31% in the North Central
region. Given the different geographical distribution of the two samples and the potential impact geographical
areas can have on the incidence of IPF, the comparison cannot be made based on crude rates.
Epidemiological studies of IPF have also provided varying findings because data were collected from
different sources: national registers, single centres or regions, and healthcare and administrative databases.
All of these methods have their advantages and drawbacks [7]. The Canadian study [3], the study by
RAGHU et al. [1] and our study [4] used administrative databases that permit analyses of large populations,
but their limit is that correct diagnosis of IPF cannot be ascertained.
We believe that in epidemiology it is very important to examine the methodology used in each individual
study, since this can impact incidence and prevalence data due to “technical” factors and data may be
compared although they are not actually comparable. Moreover, methodological rigour can make a difference.
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From the authors:
Idiopathic pulmonary fibrosis (IPF) is a very complex disease and despite the diagnostic criteria published
in evidence-based guidelines in 2011, there are significant pitfalls in making an accurate diagnosis of IPF
[1]. This has surfaced as a reason for the high rate of screen failures in recent prospective clinical trials for
IPF [2–5]. Since epidemiological studies are simply based on data entered in medical records and health
claim databases, and are not subject to validation by review of actual raw data by experienced experts and
multidisciplinary discussions among experts in the field of interstitial lung disease, the reports of the
incidence and prevalence of IPF can only be estimates of diagnosis made on assumptions and, thus, must
be interpreted with caution. Indeed, tracking the true occurrence of IPF is challenging [6].
The case definition used to identify patients with IPF in our study was not validated. Besides, false
positives may well have been a problem and without correction for false positives, the algorithms used to
estimate the incidence and prevalence of IPF may be an overestimate by as much as 50% [7, 8].
In this regard, the correspondence from S. Harari and colleagues is very much appreciated as it surfaces
other concerns with epidemiological studies and methodological issues associated with estimating
incidence and prevalence of disease in the USA, Canada and beyond. We agree that such methodological
issues must be considered in appreciating and understanding the differences in reports from different
studies. Indeed, we had acknowledged the limitations in our study as well.
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